Table 3

Serum albumin and survival - female cancers

First author, year of publication, place

Year of data collection

Study design, Sample size

Cancer type

Groups being compared

RR (95%Cl), p-value

Variables adjusted for

Gupta D, 2009, USA [77]

January 2001 to May 2006

Retrospective, consecutive case series, 213

Ovarian

>=3.5 g/dL

<3.5 g/dL

Used as continuous as well

Univariate: median survival in months (95%CI)

Low: 7.3 (4.8 to 9.8)

Normal: 23.3 (16.5 to 30.1); p < 0.0001

Multivariate: 0.39 (0.29-0.53), <0.001

Age, BMI, CA125, tumor stage, treatment history

Sharma R, 2008, UK [78]

October 2003 to June 2006

Retrospective, 154

Ovarian

<3.5 g/dL

>=3.5 g/dL

Univariate: 1.71 (0.92-3.18), 0.091

GPS score was prognostic on multivariate analysis

Tumor type, stage, grade, ascites, debulking surgery, ALP, residual disease, CRP

Alphs HH, 2006, USA [79]

January 1,

1990 to June 30, 2004

Retrospective, 78

Ovarian and primary peritoneal

>=3.7 g/dL

<3.7 g/dL

Univariate: 0.58 (0.42-0.79), p < 0.00

Multivariate: 0.60 (0.41-0.89), p = 0.01

Age, race, BMI, Co-morbidity index, surgeon, ASA score, tumor size, intraoperative blood loss, ascites

Lis CG, 2003, USA [46]

March 1993 to December 1999

Retrospective consecutive case series, 180

Breast

>=3.5 g/dL

<3.5 g/dL

Multivariate: 3.53, 0.0033

Abnormal breast antigen, tumor stage, abnormal HER2/Neu readings

Wyld L 2003, UK [80]

January 1997 to January 2002

Retrospective, 145

Breast cancer with liver metastases

First group

<3.0 g/dL

>=3.0 g/dL

Second group

<3.5 g/dL

>=3.5 g/dL

Median survival in months (95%CI)

For first group

>=3.0 g/dL = 5.86 (0.16 - 51)

<3.0 g/dL = 1.5 (0.16 - 5.13), p = 0.01

For Second group

>=3.5 g/dL = 7.0 (0.27 - 51)

<3.5 g/dL = 2.0 (0.16 - 27.2) p = 0.01

LFTs, CEA, bilirubin, age, histological grade, ER status, metastasis, treatment response

Clark TG, 2001, UK [81]

01/01/1984 to 31/12/1999

Retrospective, 1189

Ovarian

Continuous variable

Univariate: p <= 0.05

Multivariate: 0.97 (0.96, 0.99), 0.036

Age, FIGO stage, the presence

or absence of ascites, performance status, histology, debulking, grade, CA125 and ALP

Gupta and Lis Nutrition Journal 2010 9:69   doi:10.1186/1475-2891-9-69